Innoviva (INVA) Accumulated Expenses (2010 - 2026)
Innoviva (INVA) posted Accumulated Expenses of $231000.0 for Q1 2026, down 99.22% on a QoQ basis from $29.5 million in Q4 2025, and down 72.27% year-over-year from $833000.0 in Q1 2025.
Innoviva (INVA) Accumulated Expenses (2010 - 2026) Analysis & Trends
Innoviva's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $231000.0 for Q1 2026.
- Quarterly Accumulated Expenses fell 72.27% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231000.0 (down 72.27% YoY) and the FY2025 annual result came in at $29.5 million, down 1.77% from the prior year.
- Accumulated Expenses was $231000.0 for Q1 2026 at Innoviva, down from $29.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $30.0 million in Q4 2024 and bottomed at $231000.0 in Q3 2025.
- A 5-year average of $6.1 million and a median of $3.4 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 616.09% — and 2025, when it tumbled 96.13%.
- Innoviva's Accumulated Expenses stood at $4.4 million in 2022, then surged by 61.05% to $7.0 million in 2023, then jumped by 327.34% to $30.0 million in 2024, then slipped by 1.77% to $29.5 million in 2025, then slumped by 99.22% to $231000.0 in 2026.
- Business Quant data shows INVA's Accumulated Expenses at $231000.0 in Q1 2026, $29.5 million in Q4 2025, and $231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231,000.00 |
| Dec 31, 2025 | 29.47 Mn |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | 3.42 Mn |
| Mar 31, 2025 | 833,000.00 |
| Dec 31, 2024 | 30.00 Mn |
| Sep 30, 2024 | 5.97 Mn |
| Jun 30, 2024 | 3.42 Mn |
| Mar 31, 2024 | 833,000.00 |
| Dec 31, 2023 | 7.02 Mn |
| Sep 30, 2023 | 833,000.00 |
| Jun 30, 2023 | 3.42 Mn |
| Mar 31, 2023 | 833,000.00 |
| Dec 31, 2022 | 4.36 Mn |
| Sep 30, 2022 | 6.47 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 4.15 Mn |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 4.15 Mn |